The PolyNovo Ltd (ASX: PNV) share price is on the move on Tuesday following the release of a trading update.
In morning trade the medical device company’s shares are down a disappointing 10% to $3.04.
What did PolyNovo announce?
PolyNovo’s update revealed that the company delivered a 31% increase in sales over the prior corresponding period for the first half of FY 2021.
This was driven largely by a 75% increase in sales during the first quarter, which was offset slightly by slower than expected sales in October and November.
Pleasingly, this softness appears to have ended, with the company’s December sales growing strongly and coming in ahead of expectations in the US, New Zealand, and Taiwan markets.
In respect to the key US market, PolyNovo’s sales grew 41% during the first half. It is aiming to build on this in the second half with the help of recent appointments.
During the half, PolyNovo hired 12 experienced and dedicated Territory Managers and one sales director in the country. It also notes that it received more requests for proposal (RFP) in the last three months than in the previous nine months, signed two GPOs, and a number of large strategic hospitals.
Management commentary.
PolyNovo’s Chairman, David Williams, revealed that COVID-19 had impacted its performance during the first half.
He said: “While we have experienced a few bumps from COVID-19, we have built a significant base of new customers which holds us in a strong position. We will continue to expand our customer base which will enhance our success as the pandemic eases.”
The company’s Managing Director, Paul Brennan, acknowledges that the near term will be volatile, but remains very positive on the long term.
He commented: “In the short-term forecasting sales will be challenging particularly in the US, however the medium-term outlook is strong, and we continue to see surgeons using and referring NovoSorb BTM to their peers. Once hospitals have more capacity, we will see US and UK sales accelerate just as we have seen in New Zealand and Australia. New geographies offer good opportunities for NovoSorb BTM.”
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- These were the worst performing ASX 200 shares last week
- 3 mid cap shares hitting 1-month lows on the ASX today
- Are these 4 ASX medical shares set for a healthy 2021?
- ASX 200 drops 1.1%
- Here’s why the PolyNovo (ASX:PNV) share price zoomed 97% higher in 2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the PolyNovo (ASX:PNV) share price is sinking 10% lower today appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/35vIWdW
Leave a Reply